IL13 and ancylostomiasis: IL-33 protects against experimental cerebral malaria by driving the expansion of ILC2s and their production of IL-4, IL-5 and IL-13 [100] and is required for ILC2-derived IL-13- but not IL-4-driven Type 2 responses during hookworm infection [101].